Novartis is working to develop a diverse portfolio of compounds that protect and restore vision. We are looking for truly differentiating first or best-in-class treatments in:
- Geographic atrophy (GA)
- Intermediate AMD (iAMD)
- Stargardt disease
- Glaucoma neuroprotection
- Genotype agnostic IRD therapies
Christopher Adams
We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to:
- Enable deeper understanding of disease
- Power small and large molecule design
- Increase predictive safety
- Improve trial design
Cynthia Hong
Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including emerging and tropical infectious diseases.
Charles Bailey
We understand that innovation happens outside of our areas of interest and are prepared to discuss transformational areas.